Melatonin: Adjuvant therapy of malignant tumors

Medical Science Monitor

Volumn 14, Issue 5, 2008, Pages

  Dziegiel, Piotr ^a   Podhorska Okolow, Marzena ^a   Zabel, Maciej ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Adjuvant therapy; Malignant tumors; Melatonin

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYTOSTATIC AGENT; DAUNORUBICIN; DOXORUBICIN; MELATONIN; METHOTREXATE; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BEDTIME DOSAGE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL ANIMAL; HUMAN; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HORMONES; HUMANS; IMMUNE SYSTEM; MALE; MELATONIN; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 43549124355     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Lerner AB, Case JD, Takahashi Y et al: Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc, 1958; 80: 2587
2. Lerner AB, Case JD Heinzelman RU: Structure of melatonin. J Am Chem Soc, 1959; 81: 6084-85
3. Pandi-Perumal SR, Sirnivasan V, Maestroni GJM et al: Melatonin: Nature's most versatile biological signal? FEBS J, 2006; 273: 2813-38
4. Konturek SJ, Konturek PC, Brzozowski T: Melatonin in gastroprotection against stress-induced acute gastrin lesions and In healing of chronic gastrin ulcers. J Physiol Pharmacol, 2006; 57(Suppl.5): 51-66
5. Tan DX, Manchester LC, Terron MP et al: One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res, 2007; 42: 28-42
6. Liu T, Borjigin J: N-acetyltrnasferase is not the rate-limiting enzyme of melatonin synthesis at night. J Pineal Res, 2005; 39: 91-96
7. Cagnacci A: Melatonin in relation to physiology in adult humans. J Pineal Res, 1996; 21: 200-13
8. Karasek M, Winczyk K: Melatonin in humans. J Physiol Pharmacol, 2006; 57(Suppl.5): 19-39
9. Macchi MM, Bruce JN: Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol, 2004; 25: 177-95
10. Liebmann PM, Wölfer A, Felsner P et al: Melatonin and the immune system. Int Arch Allergy Immunol, 1997; 112: 203-11
11. Karasek M, Lewinski A, Reiter RJ: Melatonin: clinical significance and therapeutic application. Pol J Endocrinol, 2001; 52: 81-100
12. Hardeland R, Pandi-Perumal SR, Cardinali DP: Melatonin. Int J Biochem Cell Biol, 2006; 38: 313-16
13. Tan DX, Manchester LC, Terron MP et al: Melatonin as a naturally occurring co-substrate of quinine reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J Pineal Res, 2007; 43: 317-20
14. Hardeland R: Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine, 2005; 27: 119-30
15. Allegra M, Reiter RJ, Tan D-X et al: The chemistry of melatonin's interaction with reactive species. J Pineal Res, 2003; 34: 1-10
16. Reiter RJ, Tan D-X, Gitto E et al: Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol J Pharmacol, 2004; 56: 159-70
17. Reiter RJ, Tan D-X, Mayo JC et al: Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim, 2003; 50: 1129-46
18. Tan D-X, Chen LD, Poeggeler B et al: Melatonin: A potent, endogenous hydroxyl radical scavenger. Endocrine J, 1993; 1: 57-60
19. Reiter RJ, Melchiori D, Sewerynek E et al: A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res, 1995; 18: 1-11
20. Reiter RJ: Oxidative damage in the central nervous system: protection by melatonin. Progr Neurobiol, 1998; 56: 359-84
21. Reiter RJ, Tan D-X, Osuna C, Gitto E: Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci, 2000; 7: 444-58
22. Colak C, Parlakpinar H, Ozer MK et al: Investigating the protective effect of melatonin on liver injury related to myocardial ischemia-reperfusion. Med Sci Monit, 2007; 13(11): BR251-54
23. Rodriguez C, Mayo JC, Sainz RM et al: Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res, 2004; 36: 1-9
24. Dreher D, Junod AF: Role of oxygen free radicals in cancer development. Eur J Cancer, 1996; 32A: 30-38
25. De Zwart LL, Meerman JHN, Commandeur JNM, Vermeulen NPE: Biomarkers of free radical damage applications in experimental animals and in humans. Free Radic Biol Med, 1999; 26: 202-25
26. Zhang Z, Inserra PF, Liang B et al: Melatonin, immune modulation and aging. Autoimmunity, 1997; 26: 43-53
27. Maestroni GJ, Conti A: Anti-stress role of the melatonin-immuno-opioid network: evidence for a physiological mechanism involving T cell-derived, immunoreactive beta-endorphin and MET-enkephalin binding to thymic opioid receptors. Int J Neurosci, 1991; 61: 289-98
28. Maestroni GJ, Conti A: Immuno-derived opioids as mediators of the immuno-enhancing and anti-stress action of melatonin. Acta Neurol, 1991; 13: 356-60
29. Carrillo-Vico A, Reiter RJ, Lardone PJ et al: The modulatory role of melatonin on immune responsiveness. Curr Opin Investig Drugs, 2006; 7: 423-31
30. Miller SC, Pandi PSR, Esquifino AI et al: The role of melatonin in immuno-enhancement: potential application in cancer. Int J Exp Path, 2006; 87: 81-87
31. Conti A, Conconi S, Hertens E et al: Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res, 2000; 28: 193-202
32. Pioli C, Caroleo MC, Nistico G, Doria G: Melatonin increases antigen presentation and amplifies specific and non specific signals for T-cell proliferation. Int J Immunopharmacol, 1993; 15: 463-68
33. Lissoni P, Barni S, Brivio F et al: A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia. Oncology, 1995; 52: 360-62
34. Poon AM, Liu ZM, Pang CS et al: Melatonin implant decreases the density of 2[125I]iodomelatonin binding sites in the chicken spleen. Biol Signals, 1994; 3: 107-17
35. Blask DE, Hill SE: Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. J Neural Transm Suppl, 1986; 21: 433-49
36. Hill SE, Blask DE: Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res, 1988; 48: 6121-26
37. Wilson ST, Blask DE: Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. J Clin Endocrinol Metab, 1992; 75: 669-70
38. Cos S, Blask DE, Lemus-Wilson A, Hill AB: Effects of melatonin on the cell cycle kinetics and "estrogen-rescue" of MCF-7 human breast cancer cells in culture. J Pineal Res, 1991; 10: 36-42
39. Sánchez-Barceló EJ, Cos S, Fernández R, Mediavilla MD: Melatonin and mammary cancer: a short review. Endocr Relat Cancer, 2003; 10: 153-59
40. Walker MJ, Chaudhuri PK, Beattie CW et al: Neuroendocrine and endocrine correlates to hamster melanoma growth in vitro. Surg Forum, 1978; 29: 151-52
41. Bartsch C, Bartsch H: The link between the pineal gland and cancer: An interaction involoving chronobiological mechanisms. In: Halberg F, Reale, L Tarquini B (eds). Chronobiological Approach to Social Medicine. Roma: Instituto Italiano di Medicine Sociale, 1984; 105-26
42. Bartsch H, Bartsch C, Flehmig B: Differential effect of melatonin on slow and fast growing passages of a human melanoma cell line. Neuroendocrinol Lett, 1986; 289-93
43. Slominski A, Pruski D: Melatonin inhibits proliferation and melanogenesis in rodent melanoma cells. Exp Cell Res, 1993; 206: 189-94
44. Kurakousis CP, Lopez RE, Bhakoo HS et al: Estrogen and progesterone receptors and tamoxifen in malignant melanoma. Cancer Treat Rep, 1980; 64: 819-27
45. Gill PG, De Young NJ, Thompson A et al: The effect of tamoxifen on the growth of human malignant melanoma in vitro. Eur J Cancer Clin Oncol, 1984; 20: 807-15
46. Taylor CM, Blanchard B, Zava DT: Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res, 1984; 44(4):1409-14
47. Walker MJ, Beattie CW, Patel MK et al: Estrogen receptor in malignant melanoma. J Clin Oncol, 1987; 5: 1256-61
48. Leone AM, Silman RE, Hill BT: Growth inhibitory effects of melatonin and its metabolites against ovarian tumor cells in vitro. In: Gupta D, Attanasio A, Reiter RJ (eds). The Pineal Gland and Cancer. London: Brain Research Promotion, 1988; 273-81
49. Kikuchi Y, Kita T, Miyauchi M et al: Inhibition of human ovarian cancer cell proliferation in vitro by neuroendocrine hormones. Gynecol Oncol, 1989; 32: 60-64
50. Fic M, Podhorska-Okolow M, Dziegiel P et al: Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line Hep-2). In Vivo, 2007; 21: 513-18
51. Bartsch H, Bartsch C: Effect of melatonin on experimental tumors under different photoperiods and times of administration. J Neural Transm, 1981; 52: 269-79
52. Bartsch C, Bartsch H: The anti-tumor activity of pineal melatonin and cancer enhancing life styles in industrialized societies. Cancer Causes Control, 2006; 17: 559-71
53. Anisimov VN, Morozov VG, Khavinson VK: Comparison of the anti-tumor activity of extracts of the epiphysis and hypothalamus, melatonin and sigetin in mice with transplanted mammary gland cancer. Vopr Onkol, 1973; 19: 99-101
54. Karamali RA, Horrobin DF, Ghayur T: Role of the pineal gland in etiology and treatment of breast cancer. Lancet, 1978; 2: 1001-2
55. Wrba H, Halberg F, Dutter A: Melatonin circadian-stage-dependently delays breast tumor development in mice injected daily for several months. Chronobiologia, 1986; 13: 123-26
56. Subramanian A, Kothari L: Melatonin, a suppressor of spontaneous murine mammary tumors. J Pineal Res, 1991; 10: 136-40
57. Hamilton T: Influence of environmental light and melatonin upon mammary tumour induction. Br J Surg, 1969; 56: 764-66
58. Tamarkin L, Cohen M, Roselle D et al: Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res, 1981; 41: 4432-36
59. Shah PN, Mhatre MC, Kothari LS: Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res, 1984; 44: 3403-7
60. Blask DE: Melatonin in oncology. In: Yu HS, Reiter RJ (eds). Melatonin Biosynthesis, Physiological Effects, and Clinical Applications. Boca Raton, FL: CRC Press, 1993; 447-75
61. Subramanian A, Kothari L: Suppressive effect by melatonin on different phases of 9,10-dimethyl-1,2-benzanthracene (DMBA)-induced rat mammary gland carcinogenesis. Anticancer Drugs, 1991; 2: 297-303
62. Bartsch C, Bartsch H, Lippert TH, Gupta D: Effect of the mammary carcinogen 7,12-dimethylbenz[a]anthracene on pineal melatonin biosynthesis, secretion and peripheral metabolism. Neuroendocrinology, 1990; 52: 538-44
63. Narita T, Kudo H: Effect of melatonin on B16 melanoma growth in athymic mice. Cancer Res, 1985; 45: 4175-77
64. Stanberry LR, Das Gupta TK, Beattie CW: Photoperiodic control of melanoma growth in hamsters: influence of pinealectomy and melatonin. Endocrinology, 1983; 113: 469-75
65. Reiter RJ: Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab, 2003; 17: 273-85
66. Reiter RJ: Mechanisms of cancer inhibition by melatonin. J Pineal Res, 2004; 37: 213-14
67. Lissoni P, Rovelli F, Malugani F et al: Anti-angiogenic activity of melatonin in advanced cancer patients. Neuroendocrinol Lett, 2001; 22: 45-47
68. Lissoni P, Rovelli F, Meregalli S et al: Melatonin as a new possible antiinfl ammatory agent. Biol Regul Homeost Agents, 1997; 11: 157-59
69. Lissoni P: Is there a role for melatonin in supportive care? Support Care Cancer, 2002; 10: 110-16
70. Bartsch C, Bartsch H, Karasek M: Melatonin in clinical oncology. Neuro Endocrinol Lett, 2002; 1: 30-38
71. Mazzoccoli G, Carughi S, De Cata A et al: Melatonin and cortisol serum levels in lung cancer patients at different stages of disease. Med Sci Monit, 2005; 11(6): CR284-88
72. Karasek M, Pawlikowski M: Pineal gland, melatonin and cancer. NEL Review. Neuro Endocrinol Lett, 1999; 20: 139-44
73. Korkmaz A, Reiter RJ: Epigenetic regulation: a new research are for melatonin? J Pineal Res, 2008; 44: 41-44
74. Vijayalaxmi, Reiter RJ, Tan D-X et al: Melatonin as a radioprotective agent: a review. Int J Radiation Oncology Biol Phys, 2004; 59: 639-53
75. Dziegiel P, Jethon Z, Suder E et al: Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat. Exp Toxic Pathol, 2002; 53: 433-39
76. Dziegiel P, Suder E, Surowiak P et al: Role of exogenous melatonin in reducing the nephrotoxic effect of daunorubicin and doxorubicin in the rat. J Pineal Res, 2002; 33: 95-100
77. Greish K, Sanada I, Saad A el-D et al: Protective effect of melatonin on human peripheral blood hematopoeitic stem cells against doxorubicin cytotoxicity. Anticancer Res, 2005; 25: 4245-48
78. Rapozzi V, Zorzet S, Comelli M et al: Melatonin decreases bone marrow and lymphatic toxicity of adriamycin in mice bearing TLX5 lymphoma. Life Sci, 1998; 63: 1701-13
79. Goulston E, Miller D, Barling EV et al: Sir Kenneth Starr. Med J Aust, 1977; 1: 560-62
80. Lissoni P, Barni S, Cattaneo G et al: Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology, 1991; 48: 448-50
81. Lissoni P, Bolis S, Brivio F, Fumagalli L: A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. Anticancer Res, 2000; 20: 2103-5
82. Lissoni P, Barni S, Mandala M et al: Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer, 1999; 35: 1688-92
83. Lissoni P, Chilelli M, Villa S et al: Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res, 2003; 35: 12-15
84. Vijayalaxmi, Thomas CR, Reiter RJ, Herman TS: Melatonin: from basic research to cancer treatment clinics. J Clin Oncol, 2002; 20: 2575-601
85. Cos S, Martinez-Campa C, Mediavilla MD, Sanchez-Barcelo EJ: Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res, 2005; 38: 136-42
86. Mills E, Wu P, Seely D, Guyatt G: Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res, 2005; 39: 360-66
87. Dziegiel P, Murawska-Cialowicz E, Jethon Z et al.: Melatonin stimulates the activity of protective antioxidative enzymes in myocardial cells of rats in the course of doxorubicin intoxication. J Pineal Res, 2003; 35: 183-87
88. Szulawska A, Czyz M: Molecular mechanisms of anthracyclines action. Postepy Hig Med Dosw, 2006; 60: 78-100
89. Majsterek I, Gloc E, Blasiak J, Reiter RJ: A comparison of the action of amifostine and melatonin on DNA-damaging effects and apoptosis induced by idarubicin in normal and cancer cells. J Pineal Res, 2005; 38: 254-63
90. Dziegiel P, Podhorska-Okolow M, Surowiak P et al: Influence of exogenous melatonin on doxorubicin-evoked effects in myocardium and in transplantable Morris hepatoma in rats. In Vivo, 2003; 17: 325-28
91. Dziegiel P, Surowiak P, Rabczynski J, Zabel M: Effect of melatonin on cytotoxic effects of daunorubicin on myocardium and on transplantable Morris hepatoma in rats. Pol J Pathol, 2002; 53: 201-4
92. Hara M, Yoshida M, Nishijima H et al: Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. J Pineal Res, 2001; 30: 129-38
93. Jahovic N, Cevik H, Sehirli AO et al: Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats. J Pineal Res, 2003; 34: 282-87
94. Vijayalaxmi, Reiter RJ, Meltz ML: Melatonin protects human blood lymphocytes from radiation-induced chromosome damage. Mutat Res, 1995; 346: 23-31